Epizyme (NASDAQ:EPZM) is an oncology focused biotechnology company. Its drug development platform is based on epigenetics, the science of reversible gene expression. The company's lead drugs EPZ-5676 and EPZ-6438 are currently undergoing Phase I development. The agents represent a novel class of inhibitors that target epigenetic proteins called histone methyl transferaces (HMTs). Both EPZ-5676 and EPZ-6438 are backed by substantial scientific literature showing that for each drug the associated HMT protein is a valid target in the indications under study. In addition, in preclinical studies, both compounds were successful at inhibiting the HMT targets and reversing the epigenetic factors that triggered oncogenesis. However, as in the case of all biotechnology, translation of preclinical data to humans...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|